You are here

Mirati Therapeutics

Mirati's sitravatinib in combination with nivolumab shows 37% response rate in urothelial cancer

Mirati's sitravatinib in combination with nivolumab shows 37% response rate in urothelial cancer

Seeking Alpha

Mirati Therapeutics

clinical trials

urothelial cancer

Flag link:

Top 7 Companies in Biotech Beach by Revenue

Top 7 Companies in Biotech Beach by Revenue

BioSpace

Acadia Pharmaceuticals

Mirati Therapeutics

Flag link:

Triple meeting – Mirati avoids the worst-case scenario

Triple meeting – Mirati avoids the worst-case scenario

EP Vantage

Mirati Therapeutics

colorectal cancer

Flag link:

The Week Ahead In Biotech: Adcom Test For Agile; Pfizer, Merck Lead Earnings

The Week Ahead In Biotech: Adcom Test For Agile; Pfizer, Merck Lead Earnings

Yahoo/Benzinga

Adamis Pharmaceuticals

Redhill Biopharma

Amag Pharmaceuticals

Agile Therapeutics

Agios Pharmaceuticals

Mirati Therapeutics

Sutro BioPharma

Bristol-Myers Squibb

Oyster Point Pharma

Flag link:

Mirati sets date for closely watched clinical KRAS readout

Mirati sets date for closely watched clinical KRAS readout

Fierce Biotech

Mirati Therapeutics

Flag link:

3 Companies To Watch For At November’s Society for Immunotherapy of Cancer Meeting

3 Companies To Watch For At November’s Society for Immunotherapy of Cancer Meeting

Motley Fool

cancer immunotherapy

Autolus Therapeutics

Mirati Therapeutics

Nektar Therapeutics

Flag link:

4 Biotech Stocks With Big Catalysts in September

4 Biotech Stocks With Big Catalysts in September

Motley Fool

Mirati Therapeutics

Pralsetinibdicines

Flag link:

Mirati and Novartis Pair Up to Evaluate Drug Combinations to Target KRAS G12C Mutations

Mirati and Novartis Pair Up to Evaluate Drug Combinations to Target KRAS G12C Mutations

BioSpace

Mirati Therapeutics

Flag link:

3 Cancer Stocks Given a Lift by Amgen

3 Cancer Stocks Given a Lift by Amgen

Motley Fool

Mirati Therapeutics

Array Biopharma

Gilead Sciences

Flag link:

Here's Why Mirati Therapeutics Is Surging Today

Here's Why Mirati Therapeutics Is Surging Today

Motley Fool

Mirati Therapeutics

KRAS inhibitors

Flag link:

Mirati Therapeutics Announces Positive Results in Immuno-Oncology Combination Trials

Mirati Therapeutics Announces Positive Results in Immuno-Oncology Combination Trials

CP Wire

Mirati Therapeutics

checkpoint inhibitors

non-small cell lung cancer

Flag link:

Mirati Therapeutics Announces Positive Results in Immuno-Oncology Combination Trials

Mirati Therapeutics

checkpoint inhibitors

non-small cell lung cancer

Flag link:

7 Biopharma Companies That Destroyed Shareholders Last Week

7 Biopharma Companies That Destroyed Shareholders Last Week

24/7 Wall St

Adamis Pharmaceuticals

Ocular Therapeutics

Mirati Therapeutics

Valeant Pharmacueticals

Flag link:

This Past Week’s Top 5 Biotech Movers

This Past Week’s Top 5 Biotech Movers

24/7 Wall St

Akebia Therapeutics

Clovis Oncology

Mirati Therapeutics

Flag link:

AstraZeneca Oncology Partnerships To Help Recover Sales

AstraZeneca Oncology Partnerships To Help Recover Sales

Bidness ETC

Peregrine Pharmaceuticals

Heptares Therapeutics

Mirati Therapeutics

Juno Therapeutics

Flag link:

AstraZeneca plc (ADR) Strikes 2 Immuno-Oncology Deals; Are Its Efforts In The Right Direction?

AstraZeneca plc (ADR) Strikes 2 Immuno-Oncology Deals; Are Its Efforts In The Right Direction?

Bidness, ETC

immuno-oncology

Heptares Therapeutics

Mirati Therapeutics

Flag link:

AstraZeneca ties up with little Mirati on another PD-L1 combo trial

AstraZeneca ties up with little Mirati on another PD-L1 combo trial

Fierce Biotech

PD-1 inhibitors

Mirati Therapeutics

Flag link:

Ignyta: Now Public With A Targeted Oncology Pipeline Poised For Success

Ignyta: Now Public With A Targeted Oncology Pipeline Poised For Success

Seeking Alpha

Clovis Oncology

Ariad Pharmaceuticals

Mirati Therapeutics

Puma Biotechnology

Flag link: